Potent and Fully Noncompetitive Peptidomimetic Inhibitor of Multidrug Resistance P-Glycoprotein

被引:27
作者
Arnaud, Ophelie [2 ]
Koubeissi, Ali [1 ]
Ettouati, Laurent [1 ]
Terreux, Raphael [2 ]
Alame, Ghina [4 ]
Grenot, Catherine [4 ]
Dumontet, Charles [3 ]
Di Pietro, Attilio [2 ]
Paris, Joelle [1 ]
Falson, Pierre [2 ]
机构
[1] Univ Lyon 1, Inst Sci Pharmaceut & Biol, EA Ecosyst & Mol Bioact 3741, F-69373 Lyon, France
[2] Univ Lyon 1, CNRS,UMR 5086, Inst Biol & Chim Prot,IFR BioSci Gerland Lyon Sud, Equipe Labellisee Ligue 2009,Lab Prot Resistance, F-69367 Lyon, France
[3] Univ Lyon 1, INSERM, Fac Med, Lab Cytol Analyt,U590, F-69373 Lyon, France
[4] Univ Lyon 1, INSERM, U863, F-69373 Lyon, France
关键词
MOLECULAR-FORCE FIELD; BINDING-SITES; TRANSPORTER; ANALOGS; OVEREXPRESSION; MODULATION; GEOMETRIES; AFFINITY; DISTINCT;
D O I
10.1021/jm100839w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
N-alpha-Boc-L-Asp(OBn)-L-Lys(Z)-OtBu (reversin 121, I), an inhibitor of the P-gp ABC transporter, was used to conceive compounds inhibiting the drug efflux occurring through the Hoechst 33342 and daunorubicin transport sites of P-gp, respectively H and R sites. Replacement of the aspartyl residue by trans-4-hydroxy-L-proline (4(R)Hyp) gave compounds 11 and 15 characterized by half-maximal inhibitory concentrations (1050) of 0.6 and 0.2 mu M, which are 2- and 7-fold lower than that of the parent molecule. The difference in IC50 between 11 and 15 rests on the carbonyl group of the peptidyl bond, reduced in 15. Those compounds are rather specific of P-gp, having no or limited activity on MRP1 and BCRP. 15 displayed no marked cytotoxicity up to 10-fold its IC50. Importantly, 15 equally inhibited the Hoechst 33342 and daunorubicin effluxes through a typical noncompetitive inhibition mechanism, suggesting its binding to a site different from the and R drug-transport sites.
引用
收藏
页码:6720 / 6729
页数:10
相关论文
共 44 条
[1]   Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding [J].
Aller, Stephen G. ;
Yu, Jodie ;
Ward, Andrew ;
Weng, Yue ;
Chittaboina, Srinivas ;
Zhuo, Rupeng ;
Harrell, Patina M. ;
Trinh, Yenphuong T. ;
Zhang, Qinghai ;
Urbatsch, Ina L. ;
Chang, Geoffrey .
SCIENCE, 2009, 323 (5922) :1718-1722
[2]   Inhibitors of multidrug resistance to antitumor agents (MDR) [J].
Avendaño, C ;
Menéndez, JC .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (02) :159-193
[3]  
CARDARELLI CO, 1995, CANCER RES, V55, P1086
[4]   ATPase activity of purified multidrug resistance-associated protein [J].
Chang, XB ;
Hou, YX ;
Riordan, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) :30962-30968
[5]   New application of the Julia olefination for the synthesis of Tyr-Gly E-alkene and carba isostere pseudopeptides [J].
Charrier, C ;
Ettouati, L ;
Paris, J .
TETRAHEDRON LETTERS, 1999, 40 (31) :5705-5707
[6]   Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials [J].
Colabufo, Nicola Antonio ;
Berardi, Francesco ;
Cantore, Mariangela ;
Contino, Marialessandra ;
Inglese, Carmela ;
Niso, Mauro ;
Perrone, Roberto .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (05) :1883-1897
[7]   OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].
COLE, SPC ;
BHARDWAJ, G ;
GERLACH, JH ;
MACKIE, JE ;
GRANT, CE ;
ALMQUIST, KC ;
STEWART, AJ ;
KURZ, EU ;
DUNCAN, AMV ;
DEELEY, RG .
SCIENCE, 1992, 258 (5088) :1650-1654
[8]   C-isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance [J].
Comte, G ;
Daskiewicz, JB ;
Bayet, C ;
Conseil, G ;
Viornery-Vanier, A ;
Dumontet, C ;
Di Pietro, A ;
Barron, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (05) :763-768
[9]  
Dean M, 2001, J LIPID RES, V42, P1007
[10]   A multidrug resistance transporter from human MCF-7 breast cancer cells [J].
Doyle, LA ;
Yang, WD ;
Abruzzo, LV ;
Krogmann, T ;
Gao, YM ;
Rishi, AK ;
Ross, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) :15665-15670